Abstract Cardiac calsequestrin (Casq2) is the major Ca 2? binding protein in the sarcoplasmic reticulum, which is the principle Ca 2? storage organelle of cardiac muscle. During the last decade, experimental studies have provided new concepts on the role of Casq2 in the regulation of cardiac muscle Ca 2? handling. Furthermore, mutations in the gene encoding for cardiac calsequestrin, CASQ2, cause a rare but severe form of catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we review the physiology of Casq2 in cardiac Ca 2? handling and discuss pathophysiological mechanisms that lead to CPVT caused by CASQ2 mutations. We also describe the clinical aspects of CPVT and provide an update of its contemporary clinical management.
Introduction
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic arrhythmic disorder characterized by ventricular arrhythmias, usually provoked by emotional stress or exercise, in the absence of any structural cardiac abnormality. It usually presents in young individuals in the first or second decade of life and is regarded as a highly lethal disease with an overall mortality rate of 30-40 % if left untreated [53] . On a molecular level, CPVT is caused by impaired intracellular Ca 2? handling due to mutations in genes encoding for the cardiac ryanodine receptor (RyR2) [63, 72] and cardiac calsequestrin (Casq2) [42] , two main proteins forming the Ca 2? release unit of the sarcoplasmic reticulum (SR). RYR2 mutations have an autosomal dominant inheritance, whereas CASQ2 mutations are usually autosomal recessive. Compared with RyR2, Casq2-linked CPVT is much less common but often more severe clinically [64] . In contrast, the contractile function of CPVT patients is surprisingly normal [60] .
Experimental studies of Casq2-linked CPVT have been instrumental in defining the role of Casq2 in SR Ca 2? buffering and in regulating the RyR2 open probability [22, 40] . In particular, experiments in CPVT mouse models have confirmed that systolic function is preserved and demonstrated that the greater arrhythmogenic risk in CPVT can be attributed to spontaneous Ca 2? releases from the SR during diastole [34] . However, the interactions between Casq2 and the other SR proteins regulating Ca 2? releases appear to be complex, and many questions remain. Here, we review the physiology of intracellular Ca 2? handling and then focus on the pathophysiological mechanisms leading to CPVT caused by CASQ2 mutations. Finally, we describe the clinical aspects of the disease and its contemporary therapeutic management.
Physiology of Cardiac Ca 21 Handling
Excitation-Contraction Coupling Figure 1 illustrates the major protein complexes and cellular organelles involved in excitation-contraction (EC) coupling, which is the process of how an electrical signal, i.e., the cardiac action potential (AP), generates a contractile response. In cardiac EC coupling ( Fig. 1) , the cardiac cycle initiates by membrane depolarization due to ion entry through gap junction channels from a neighboring cardiomyocyte [36] . This initial depolarization opens voltage-gated Na ? channels. The ensuing Na ? current is responsible for the rapid upstroke (phase 0) of the AP. The membrane depolarization then opens voltage-gated L-type Ca 2? (Cav 1.2) channels located primarily in the transverse T-tubular membrane of cardiac myocytes (Fig. 1 triggers a much greater release of Ca 2? from the SR by way of activation of RyR2 Ca 2? release channels located in the terminal cisternae of the SR (Fig. 1) . The released Ca 2? then binds to the troponin complex, activates the contractile apparatus, and the heart contracts. [2] . Thus, in addition to Casq2, triadin and junctin should be considered as candidate genes in CPVT, although no CPVT mutations have been identified to date.
Casq2 Mutations
Human Genetics CPVT is a severe inherited arrhythmia disorder characterized by adrenergically mediated ventricular tachycardia (VT) caused by altered function of proteins composing the CRU [42, 62] . The estimated prevalence of CPVT in the population is approximately 1:10,000 [57] . Thus far, two forms of the disease have been described. One form is associated with dominant mutations in the RYR2 gene [62, 63] and is responsible of 50-55 % of all CPVT cases [53] . The other form is due to recessive mutations in the CASQ2 gene, which resides on the short arm of chromosome 1 [42, 60] and accounts for only 3-5 % of all CPVT patients [1] . Presently, 15 CASQ2 mutations have been identified in the short arm of chromosome 1: three common polymorphisms (not associated with disease) and 12 missense, deletion, and non-sense mutations (Table 1) . Interestingly, all mutations studied to date lead to either a severe decrease or complete loss of Casq2 protein [65, 68] . This observation may explain why the Casq2-linked CPVT phenotype is rather homogeneous among patients with different mutations. Heterozygous CASQ2 mutations cause approximately 25 % decrease of functional protein and do not lead to clinical CPVT per se [12] . However, based on the modest but measureable increased arrhythmia risk in heterozygous CASQ2 null mice [12] , heterozygous carriers of CASQ2 mutations may be more susceptible to ventricular arrhythmia in the presence of comorbidities affecting intracellular Ca 2? handling. Important new information on the pathophysiology of human CASQ2 mutations has been obtained from genetargeted mouse models (Table 1) [12, 34, 65, 68] . The mice largely reproduce the clinical characteristics of Casq2-linked CPVT patients, such as resting bradycardia and stress-induced polymorphic and bidirectional ventricular tachycardia (Fig. 2) , in the presence of preserved contractile function [34] . The study of these mouse models has provided new insight into the alterations of the SR ultrastructure and SR protein levels caused by CASQ2 mutations, clarified the physiological role of Casq2 in the CRU, and showed how the decrease or absence of this protein alters cardiac Ca 2? handling and causes CPVT [34] . Moreover, the CASQ2 mutant mouse models have been used as tools for in vitro and in vivo drug testing [26] . At the same time, it is unclear if this impairment in RyR2 regulation is attributable to a decrease of Casq2 itself or to the proteins that mediate binding of Casq2 to RyR2 channel (namely, triadin and junctin) [21] . Considering that almost all Casq2 mutant mouse models (including those with Casq2 overexpression) reported to date exhibited significant decrease of these Casq2-binding proteins and that mouse models with gene-targeted deletion of triadin or junctin also generated an arrhythmogenic phenotype in the absence of Casq2 mutations [13, 82] , it is possible that decrease of triadin and junctin may independently contribute to the arrhythmia risk associated with CASQ2 mutations current that depolarizes the cell membrane during diastole [7] . Such an event is termed ''delayed after-depolarization'' (DAD), which has been proposed to induce triggered activity and life-threatening ventricular arrhythmias [78] . However, to overcome the electrical sink provided by electrically coupled neighboring cells, many synchronized DADs in contiguous excitable cells are necessary to generate an impulse that propagates to the entire heart [81] . In addition, a number of studies have investigated the cell type responsible for the generation of the arrhythmic events. Most of the results so far obtained on CPVT mouse models point toward the Purkinje fibers of the specialized conduction system as the cell type responsible for arrhythmia initiation in CPVT [11, 31] . Bidirectional VT (Fig. 2) characterized by alternating QRS axis shifts and typical of CPVT syndromes has been explained as arising alternatively from the right and left bundle branch or from hemibranches of the same side [4, 54] . Most recently, computer-based CPVT models have supported this ''pingpong'' mechanism and the likely role of Purkinje fibers in CPVT due to their Ca 2? -handling characteristics, which promote spontaneous Ca 2? release and triggered activity [4, 46] (Fig. 2) . Alternatively, a pharmacological stress-test can be performed [57] . Patients usually display sporadic premature beats at the beginning of the stress (Fig. 2b) , which progress into more complex arrhythmias, such as bigeminy, couplets, and non-sustained ventricular tachycardia (Fig. 2c) as the exercise continues and more catecholamines are released [43, 63] . If the exercise is not stopped, ventricular tachycardia can become sustained and eventually lead to ventricular fibrillation and cardiac arrest. Characteristic of CPVT is bidirectional VT (Fig. 2c ) so-called because of the alternating QRS axis of the ectopic beats. However, bidirectional VT is not a pathognomonic feature because it can also be observed in other conditions, such as myocarditis, digitalis toxicity, and myocardial ischemia, as well as in a phenotypically similar but genetically distinct condition, Andersen-Tawil syndrome [8, 20, 51, 69] . Perhaps less appreciated is the potential for coexisting atrial arrhythmias in CPVT patients. Interestingly, most patients are asymptomatic during bidirectional VT, and symptoms are usually attributable to episodes of rapid polymorphic VT or ventricular fibrillation. Once a CPVT patient has been identified, first-degree relatives of the proband should be screened with 24 h Holter ECG recording and/or exercise-stress test and referred for genetic evaluation to help identify mutation carriers and early diagnose potential patients with milder or atypical phenotype.
CPVT Pathophysiology

Treatment
Conventional Therapies
As CPVT arrhythmias are provoked by catecholamine discharge in response to exertion or emotional stresses, b-blockers have long been considered as the most appropriate treatment [47, 61] . When use of b-blockers is contraindicated, or in patients symptomatic at the maximum tolerated dose of b-blockers, Ca 2? -channel blockers, such as verapamil, have been used [66, 73] . However, the efficacy of Ca 2? -channel blockers is not clear. Furthermore, despite decreasing the frequency of arrhythmic events in CPVT patients, b-blockers fail to prevent sudden cardiac death in all cases [6, 63, 71] . Up to 30 % of patients require interventional approaches, such as implantable cardioverter defibrillators (ICDs) [24] and left sympathetic denervation [3, 79] . However, these therapies are invasive and costly and are not without risk [52, 59, 61]. For example, appropriate ICD discharge in CPVT patients produces a catecholamine surge and recurrent tachycardia prompting repeated shocks; the ensuing electrical storm may prove to be lethal [52, 59, 61]. When performed properly, left sympathetic surgical ablation can decrease but may not eliminate events. In addition, such invasive approaches can have a major negative impact on the quality of life in young CPVT patients.
New Pharmacological Approaches
During the last few years, basic and translational research studies have provided new knowledge about the pivotal role of Ca 2? -handling abnormalities and RyR2/Casq2 dysfunction in CPVT pathophysiology. This led to the identification of the RyR2 as an important drug target in treating CPVT. For example, Watanabe et al. [77] found that flecainide, a class I antiarrhythmic drug, blocks RyR2 channels and holds promise as a new treatment for CPVT. Flecainide effectively decreased exercise-induced VT in ]. An S107 derivative is currently in early phase clinical trials for CPVT (Table 2 ).
Summary and Conclusion
Although CPVT caused by CASQ2 mutations is a rare clinical syndrome, the study of experimental models of CASQ2 mutations has generated a wealth of important new mechanistic insight into the role of abnormal cardiac Ca 2? handling in ventricular arrhythmias and sudden death. Moreover, the experimental work in Casq2 mutant mouse models has led to new drug therapies that have already been translated into clinical care and are likely to benefit CPVT patients for years to come. 
